149 related articles for article (PubMed ID: 3091928)
1. Liver transplantation in a 23-year-old tyrosinaemia patient: effects on the renal tubular dysfunction.
Kvittingen EA; Jellum E; Stokke O; Flatmark A; Bergan A; Sødal G; Halvorsen S; Schrumpf E; Gjone E
J Inherit Metab Dis; 1986; 9(2):216-24. PubMed ID: 3091928
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
[TBL] [Abstract][Full Text] [Related]
3. Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up.
Pierik LJ; van Spronsen FJ; Bijleveld CM; van Dael CM
J Inherit Metab Dis; 2005; 28(6):871-6. PubMed ID: 16435179
[TBL] [Abstract][Full Text] [Related]
4. Effect of dietary treatment on the renal tubular function in a patient with hereditary tyrosinemia.
Suzuki Y; Konda M; Imai I; Imamura H; Shimao S; Okaka T
Int J Pediatr Nephrol; 1987; 8(3):171-6. PubMed ID: 3429140
[TBL] [Abstract][Full Text] [Related]
5. Renal failure in adult patients with hereditary tyrosinaemia type I.
Kvittingen EA; Talseth T; Halvorsen S; Jakobs C; Hovig T; Flatmark A
J Inherit Metab Dis; 1991; 14(1):53-62. PubMed ID: 1861460
[TBL] [Abstract][Full Text] [Related]
6. Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1.
Bain MD; Purkiss P; Jones M; Bingham P; Stacey TE; Chalmers RA
Eur J Pediatr; 1990 Jun; 149(9):637-9. PubMed ID: 2373116
[TBL] [Abstract][Full Text] [Related]
7. Rapid improvement in the renal tubular dysfunction associated with tyrosinemia following hepatic replacement.
Shoemaker LR; Strife CF; Balistreri WF; Ryckman FC
Pediatrics; 1992 Feb; 89(2):251-5. PubMed ID: 1734392
[TBL] [Abstract][Full Text] [Related]
8. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone.
Fällström SP; Lindblad B; Steen G
Acta Paediatr Scand; 1981; 70(3):315-20. PubMed ID: 7246125
[TBL] [Abstract][Full Text] [Related]
9. Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.
Tuchman M; Freese DK; Sharp HL; Whitley CB; Ramnaraine ML; Ulstrom RA; Najarian JS; Ascher N; Buist NR; Terry AB
J Inherit Metab Dis; 1985; 8(1):21-4. PubMed ID: 2581063
[TBL] [Abstract][Full Text] [Related]
10. Hereditary tyrosinemia of chronic course without rickets and renal tubular dysfunction.
Søvik O; Kvittingen EA; Steen-Johnsen J; Halvorsen S
Acta Paediatr Scand; 1990 Nov; 79(11):1063-8. PubMed ID: 2267924
[TBL] [Abstract][Full Text] [Related]
11. The nephropathy of type I tyrosinemia after liver transplantation.
Laine J; Salo MK; Krogerus L; Kärkkäinen J; Wahlroos O; Holmberg C
Pediatr Res; 1995 May; 37(5):640-5. PubMed ID: 7603784
[TBL] [Abstract][Full Text] [Related]
12. Liver transplantation in nine Spanish patients with tyrosinaemia type I.
Pérez-Cerdá C; Merinero B; Sanz P; Castro M; Gangoiti J; García MJ; Díaz M; Medina E; Ugarte M
J Inherit Metab Dis; 1995; 18(2):119-22. PubMed ID: 7564224
[No Abstract] [Full Text] [Related]
13. Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase.
Gibbs TC; Payan J; Brett EM; Lindstedt S; Holme E; Clayton PT
J Neurol Neurosurg Psychiatry; 1993 Oct; 56(10):1129-32. PubMed ID: 8410015
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.
Christensen E; Jacobsen BB; Gregersen N; Hjeds H; Pedersen JB; Brandt NJ; Baekmark UB
Clin Chim Acta; 1981 Nov; 116(3):331-41. PubMed ID: 7296896
[TBL] [Abstract][Full Text] [Related]
15. Hereditary tyrosinemia: metabolic studies in a patient with partial p-hydroxyphenylpyruvate hydroxylase activity.
Jagenburg R; Landblad B; De Maré JM; Rödjer S
J Pediatr; 1972 Jun; 80(6):994-1004. PubMed ID: 5026040
[No Abstract] [Full Text] [Related]
16. Type I hereditary tyrosinaemia: presentation of 11 cases.
Coşkun T; Ozalp I; Koçak N; Yüce A; Caglar M; Berger R
J Inherit Metab Dis; 1991; 14(5):765-70. PubMed ID: 1664010
[TBL] [Abstract][Full Text] [Related]
17. Urinary succinylacetone presence and delta-aminolaevulinic acid excretion in patients with type I tyrosinaemia during treatment.
Pronicka E; Mielniczuk Z; Rowińska E; Ksiazyk J; Szczygielska-Kozak M; Wieczorek E; Kulczycka H
Mater Med Pol; 1991; 23(2):136-8. PubMed ID: 1842600
[TBL] [Abstract][Full Text] [Related]
18. Tyrosinaemia type Ia without excess of urinary succinylacetone.
Biasucci G; Giuffré B; La Grutta S; Riva E
J Inherit Metab Dis; 1993; 16(6):1056-7. PubMed ID: 8127063
[No Abstract] [Full Text] [Related]
19. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
Pronicka E; Rowinska E; Bentkowski Z; Zawadzki J; Holme E; Lindstedt S
J Inherit Metab Dis; 1996; 19(2):234-8. PubMed ID: 8739974
[No Abstract] [Full Text] [Related]
20. Urinary excretion of deuterated metabolites in patients with tyrosinemia type I after oral loading with deuterated L-tyrosine.
Wadman SK; Duran M; Ketting D; Bruinvis L; van Sprang FJ; Berger R; Smit GP; Steinmann B; Leonard JV; Divry P; Farriaux JP; Cartigny B
Clin Chim Acta; 1983 May; 130(2):231-8. PubMed ID: 6872257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
